DRAFT-STRICTLY CONFIDENTIAL


Too Gourmet, Inc. Completes Acquisition of Assets of German
Medical Laboratory

Irvine, CA, November 5, 2003.Too Gourmet, Inc.-OTCBB:TGOU is
pleased to announce that it has completed the acquisition of
the medical business assets and related intellectual
property of a medical laboratory and service provider, doing
business as the Internationale Fachklinik ("lab") located in
Schwerin, Germany from Prof. Dr. Hans-Jurgen Reimann and Dr.
Antje Reimann.

In connection with the acquisition, Prof. Reimann will be
appointed to serve as the company's Chairman of the Board
and as its Chief Executive Officer.  Dr. A. Reimann will
also be appointed to the Board of Directors of the company.
The international law firm of Bryan Cave llp will continue
its engagement with the company as its corporate securities
counsel.

Under the direction of Prof. Reimann, Professor at
University of Rostock and at Humboldt University in Berlin,
Germany, Ph.D. in Biochemistry and Ph.D. in Medicine, the
lab specializes in the research, analysis, and in vitro
diagnosis of live biopsy tissue samples for allergic,
immunological, and environmentally related disorders.  In
order to improve the quality of test results, Prof. Reimann
developed and patented a unique device, known as a "Tabox",
which enables the precise analysis of the effects of
allergens and toxins on the human body in an in vitro
environment.

Currently, the lab operates a total of twenty-eight inter-
clinic Tabox systems as proprietary devices, which are
available to practitioners, clinics, and other medical
clients on a lease-only basis.  The lab charges its lessees
a user fee for each tissue sample processed at the lab.
According to Prof. Reimann, the operation of twenty-eight
Tabox systems at capacity could generate revenues of up to
$2.8 million annually.  Prof. Reimann anticipates the
production and use of up to one hundred Tabox systems by its
clients by the end of the third quarter of 2004.  During the
2033 calendar year, the lab has reported revenues of
approximately $1.2 million and pre-tax profits of
approximately 30% of sales.

The company is in preliminary negotiations to acquire all of
the outstanding stock of a German medical devices,
equipment, and apparatus manufacturer that currently
produces the Tabox for the lab.  "The purchase of the
equipment manufacturer could be a strategic acquisition,
ensuring timely production and commercial "roll out" of the
proprietary Tabox systems and expansion of the lab's
services in Western Europe," said Prof. Reimann.  "In
addition, the manufacturer's fiscal performance could
contribute significantly to the company's revenues and
earnings in 2004.  Furthermore, the acquisition of the
manufacturer could help to diversify the company's products
and services portfolio into other potentially profitable,
niche markets."  The manufacturer anticipates revenues of
approximately $7.5 million and pre-tax profits of
approximately $2.0 million in the current calendar year
2003.

The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for forward-looking statements.
Certain information included in this press release contains
statements that are forward-looking, such as statements
related to the future anticipated direction of the industry,
plans for future expansion, various business development
activities, planned capital expenditures, future funding
sources, anticipated sales growth, and potential contracts.
Such forward-looking information involves important risks
and uncertainties that could significantly affect
anticipated results in the future and, accordingly, such
results may differ from those expressed in any forward-
looking statements made by, or on behalf of Too Gourmet,
Inc.  These risks and uncertainties include, but are not
limited to, those relating to development and expansion
activities, dependence on existing management, financing
activities, and domestic and global economic conditions.


Contact:
Too Gourmet, Inc.
Attention: c/o  R. Katz
Phone:  949-223-7103